Physician profile
Thomas E Bump
NPI 1013941053
$1,932.96
in general payments reported to CMS, 2019-2025
26 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $82.47 · 2021: $264 · 2022: $445 · 2023: $349 · 2024: $254 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $287.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $202.28 | 2019-2025 | |
| Novo Nordisk INC | $159.68 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $149.35 | 2021-2023 | Cobalt Dr Mri Surescan |
| Amgen INC. | $133.69 | 2021-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.02 | 2020-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $106.33 | 2021-2025 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $84.64 | 2022 | |
| Cardiva Medical, INC. | $71.31 | 2024 | Cardiva Vascade 6/7f Vcs |
| Astrazeneca Pharmaceuticals Lp | $69.85 | 2021-2025 | Brilinta, Lokelma, Farxiga |
| Pfizer INC. | $68.58 | 2023-2024 | |
| Boston Scientific Corporation | $54.98 | 2019-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.15 | 2021-2025 | Jardiance |
| Abbott Laboratories | $50.66 | 2023-2025 | Mitraclip, Cardiomems |
| Edwards Lifesciences Corporation | $48.65 | 2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $46.13 | 2025 | Alphavac |
| Daiichi Sankyo INC. | $41.08 | 2024 | Injectafer |
| Alnylam Pharmaceuticals INC. | $38.70 | 2019-2025 | Amvuttra |
| Biotronik INC. | $27.43 | 2024 | Pulsar-18 T3, Passeo-18 |
| Portola Pharmaceuticals, LLC | $22.94 | 2019 | |
| Inspire Medical Systems, INC. | $21.39 | 2024 | Inspire |
| Astellas Pharma US INC | $20.49 | 2022 | |
| Preventice Services, LLC | $17.39 | 2019 | |
| Atricure, INC. | $17.31 | 2023 | |
| Cordis US Corp. | $16.88 | 2022 | |
| Jubilant Draximage INC. | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bump listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.